Výsledky vyhledávání

Evidence of interferon beta-1a dose response in relapsing-remitting MS - The OWIMS study

Autor: Ebers, G., Lee, D., Rice, G., Lesaux, J., Kennedy, K., Sanders, Eacm, Versteylen, Rj, Andel, Jd, Story, Jp, Milliano, M., O Connor, P., Cheung, G., Houston, P., Hall, J., Comi, G., Massimo Filippi, Martinelli, V., Santuccio, G., Poggi, A., Gironi, M., Moiola, L., Duquette, P., Bourgouin, P., Pepin, G., Poirer, J., Bernier, G., Dubois, R., Metz, L., Diamond, Rt, Bell, R., Mcgowan, D., Demchuk, A., Harris, E., Yeung, M., Murphy, A., Murray, Tj, Vandorpe, R., Bhan, V., Maxner, C., Weldon, P., Armstrong, L., Bouchard, Jp, Grondin, P., Gosselin, F., Thibaut, M., Kirouac, L., Morin, A., Abramsky, O., Gomori, Jm, Karussis, D., Karni, A., Mor, M., Freedman, Ms, Avruch, L., Nelson, R., Christie, S., Rabinovitch, H., Freedman, C., Benavente, M., Pelletier, J., Levrier, O., Bensa, P., Dalesky, A., Paty, D., Li, D., Rhodes, B., Riddehough, A., Zhao, G., Wang, X., Chang, Y., Abdul-Ahad, A., Ammoury, N., Dupont, F., Francis, G., Furcha, R., Galazka, A., Hyde, R., Olson, M., Pernin, Mo, Shah, S., Freedman, M., Murray, J.

Publikováno v: Publons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::341266ef4201f85a9f7c81b9cf4e9915

Zobrazit plný text záznamu

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

Autor: Ebers, GC, Rice, G, Lesaux, J, Paty, D, Oger, J, Li, DKB, Beall, S, Devonshire, V, Hashimoto, S, Hooge, J, Kastrukoff, L, Krieger, C, Mezei, M, Seland, P, Vorobeychi, G, Morrison, W, Nelson, J, Freedman, MS, Chrisie, S, Nelson, R, Rabinovitch, H, Freedman, C, Hartung, HP, Rieckmann, P, Archelos, J, Jung, S, Weilbach, F, Flachenecke, P, Sauer, J, Hommes, O, Jongen, P, Brouwer, S, McLeod, J, Pollard, J, Ng, R, Sandberg-Wollheim, M, Kallen, K, Nilsson, P, Ekberg, R, Lundgren, A, Jadback, G, Wikstrom, J, Multanen, J, Valjakka, M, Carton, H, Lissoir, F, Declerq, I, Vieren, M, Peeters, E, Dubois, B, Dekeersmaeker, E, Van Herle, A, Hughes, RAC, Sharrack, B, Soudain, S, Panelius, M, Eralinna, J, Soilu-Hanninen, M, Murto, S, Medaer, R, Broeckx, J, Vanroose, E, Bogaers, A, Blumhardt, LD, Edwards, S, Liu, C, Orpe, V, Barnes, D, Schwartz, M, Stoy, N, Harraghy, C, Bertelsmann, F, Uitdehaag, B, Nasseri, K, Chofflon, M, Roth, S, Kappos, L, Huber, S, Bellaiche, Y, Senn, C, King, J, Jubert, J, Whitten, S, Newsom-Davis, JM, Palace, J, Lee, M, Evangelou, N, Pinto, A, Cavey, A, Sindic, CJM, Monteyne, P, Verougstraete, D, Van Doorn, PA, Moll, W, Visser, L, Willems, M, Martina, I, Buljevac, D, Loman, L, Bates, D, Pandit, D, Irving, J, Rhodes, B, Riddehough, A, Zhao, GJ, Wang, X, Cheng, Y, Ammoury, N, Dupont, F, Galazka, A, Hyde, R, Olson, M, Pernin, MO, Abdul-Ahad, AK, Noseworthy, J, Borden, E, O'Brien, P, Wolinsky, J, Grp, PRISMSS

Publikováno v: Lancet. 352(9139)

BACKGROUND: Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::5693c22c46bfd03de445cd73b4162e50
http://ora.ox.ac.uk/objects/uuid:61d8908f-d676-4725-b673-220d6d81871c